Patents by Inventor Andrej Bastarda
Andrej Bastarda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9453030Abstract: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.Type: GrantFiled: December 18, 2014Date of Patent: September 27, 2016Assignee: Lek Pharmaceuticals d.d.Inventors: Rok Grahek, Darko Kocjan, Andrej Bastarda, Andrej Kocijan, Matjaz Kracun
-
Publication number: 20150105551Abstract: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventors: Rok GRAHEK, Darko KOCJAN, Andrej BASTARDA, Andrej KOCIJAN, Matjaz KRACUN
-
Patent number: 8435938Abstract: The new pure vancomycin hydrochloride substantially free of impurities known in commercially available products is described. The term “substantially free of impurities” designates a purity of vancomycin hydrochloride between about 97% and about 99%, particularly between about 98% and about 99%, preferably about 99%, as determined by HPLC analytical method as directed in U.S.P., NF 27th revision, 22 (2004). The new pure vancomycin hydrochloride (vancomycin B hydrochloride) contains less than 0.7% of total impurities, namely, only one impurity exceeds 0.3%. The new process for the purification of crude vancomycin by displacement chromatography is described by which the desired pure antibiotic according to the present invention is produced, based on the finding that high purity of the vancomycin hydrochloride is obtained using low selected pH values of the mobile phase between 3.9 and 4.2.Type: GrantFiled: December 5, 2005Date of Patent: May 7, 2013Assignee: Lek Pharmaceuticals d.d.Inventors: Rok Grahek, Andrej Bastarda
-
Patent number: 8309719Abstract: Process for the preparation of enantiomerically pure methyl ester of rosuvastatin has been developed, wherein the crude methyl ester ester is first purified by preparative chromatography, followed by crystallization.Type: GrantFiled: August 1, 2008Date of Patent: November 13, 2012Assignee: LEK Pharmaceuticals D.D.Inventors: Andrej Bastarda, Rok Grahek, Martin Crnugelj
-
Publication number: 20120088774Abstract: The present invention belongs to the field of pharmaceutical industry and relates to dosage forms comprising active pharmaceutical ingredients (API) such as tadalafil, simvastatin, fenofibrate and lovastatin that are practically insoluble in water, adsorbed on a carrier. Furthermore it relates to an adsorbate comprising API being practically insoluble in water and to a process for the preparation of said adsorbate with non-polar solvent (s) such as chlorinated hydrocarbon, diisopropylethes and hexane. Furthermore the invention relates to a process for the preparation of the dosage form, as well as to the use of the adsorbate for the preparation of the dosage form. Moreover it relates to the dosage form for use in the treatment of erectile dysfunction, human immunodeficiency virus (HIV) infections and/or Acquired Immune Deficiency Syndrome (AIDS).Type: ApplicationFiled: April 6, 2010Publication date: April 12, 2012Applicant: LEK PHARMACEUTICALS D.D.Inventors: Rok Grahek, Andrej Bastarda, Miha T. Jaklic, Klemen Kocevar, Samo Pirc
-
Patent number: 8044086Abstract: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.Type: GrantFiled: July 15, 2005Date of Patent: October 25, 2011Assignee: Lek Pharmaceuticals D.D.Inventors: Rok Grahek, Darko Kocjan, Andrej Bastarda, Andrej Kocijan, Matjaz Kracun
-
Publication number: 20110184172Abstract: Process for the preparation of enantiomerically pure methyl ester of rosuvastatin has been developed, wherein the crude methyl ester ester is first purified by preparative chromatography, followed by crystallization.Type: ApplicationFiled: August 1, 2008Publication date: July 28, 2011Applicant: LEK PHARMACEUTICALS D.D.Inventors: Andrej Bastarda, Rok Grahek, Martin Crnugelj
-
Publication number: 20110112165Abstract: A new compound in which atorvastatin and aliskiren are covalently bound, salts of this compound, pharmaceutical compositions thereof, as well the use of this compound as a medicament and as an impurity standard are provided. Furthermore, a 0 process for the preparation of a compound in which atorvastatin and aliskiren are covalently bound, a method for analyzing a sample of atorvastatin and/or aliskiren, and a method for determining the retention time on a chromatographic system for atorvastatin and/or aliskiren are provided.Type: ApplicationFiled: January 13, 2009Publication date: May 12, 2011Inventors: Andrej Kocijan, Matjaz Kracun, Andrej Bastarda, Rok Grahek, Darko Kocjan
-
Publication number: 20100305087Abstract: A combination preparation comprising an active pharmaceutical ingredient (API) and a pharmaceutically acceptable solid support, wherein said solid support is in a water-insoluble particulate form and comprises a material selected from silicic acid, aluminum hydroxide and titanium hydroxide is disclosed. The API is a compound having both, at least one hydrophobic structural moiety causing the API to have a low solubility in water or in an aqueous solution, and multiple hydrophilic groups arranged to form multiple intermolecular interactions to the solid support involving polar or ionic or hydrogen bonding. The hydrophilic groups of the API are independently equal or different and comprise at least one of the groups consisting of OH- and halogen-groups. The API is bound to the solid support by adsorption, and a major proportion of said API is in an amorphous state. Related pharmaceuticals and methods of preparation also are disclosed.Type: ApplicationFiled: December 18, 2008Publication date: December 2, 2010Applicant: Lek Pharmaceuticals d.d.Inventors: Rok Grahek, Aleksander Resman, Andrej Bastarda, Martin Crnugelj
-
Publication number: 20100219063Abstract: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.Type: ApplicationFiled: April 30, 2010Publication date: September 2, 2010Applicant: Lek Pharmaceuticals D.D.Inventors: Rok GRAHEK, Darko Kocjan, Andrej Bastarda, Andrej Kocijan, Matjaz Kracun
-
Publication number: 20100190958Abstract: The new pure vancomycin hydrochloride substantially free of impurities known in commercially available products is described. The term “substantially free of impurities” designates a purity of vancomycin hydrochloride between about 97% and about 99%, particularly between about 98% and about 99%, preferably about 99%, as determined by HPLC analytical method as directed in U.S.P., NF 27th revision, 22 (2004). The new pure vancomycin hydrochloride (vancomycin B hydrochloride) contains less than 0.7% of total impurities, namely, only one impurity exceeds 0.3%. The new process for the purification of crude vancomycin by displacement chromatography is described by which the desired pure antibiotic according to the present invention is produced, based on the finding that high purity of the vancomycin hydrochloride is obtained using low selected pH values of the mobile phase between 3.9 and 4.2.Type: ApplicationFiled: December 5, 2005Publication date: July 29, 2010Applicant: LEK PHARMACEUTICAL D.D.Inventors: Rok Grahek, Andrej Bastarda
-
Publication number: 20100056605Abstract: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.Type: ApplicationFiled: November 6, 2009Publication date: March 4, 2010Applicant: LEK PHARMACEUTICALS D.D.Inventors: Rok Grahek, Darko Kocjan, Andrej Bastarda, Andrej Kocijan, Matjaz Kracun
-
Publication number: 20090012150Abstract: The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of atorvastatin calcium in an amorphous form is described.Type: ApplicationFiled: October 24, 2007Publication date: January 8, 2009Inventors: Rok Grahek, Andrej Bastarda, Mateja Salobir
-
Publication number: 20070208071Abstract: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.Type: ApplicationFiled: July 15, 2005Publication date: September 6, 2007Applicant: LEK PHARMACEUTICALS D.D.Inventors: Rok Grahek, Darko Kocjan, Andrej Bastarda, Andrej Kocijan, Matjaz Kracun
-
Publication number: 20070032549Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment.Type: ApplicationFiled: October 16, 2006Publication date: February 8, 2007Inventors: Rok Grahek, Dusan Milivojevic, Andrej Bastarda
-
Patent number: 7141602Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment.Type: GrantFiled: October 30, 2003Date of Patent: November 28, 2006Assignee: LEK Pharmaceuticals d.d.Inventors: Rok Grahek, Dusan Milivojevic, Andrej Bastarda
-
Publication number: 20040138294Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, Streptomyces, Actinomadura, Micromonospora, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment.Type: ApplicationFiled: October 30, 2003Publication date: July 15, 2004Inventors: Rok Grahek, Dusan Milivojevic, Andrej Bastarda
-
Publication number: 20040077708Abstract: The invention relates to the pharmaceutical composition comprising the amorphous active substance which is atorvastatin calcium. The process of stabilization of the pharmaceutical composition comprising the pharmaceutical formulation with amorphous atorvastatin calcium, the process of stabilization of the pharmaceutical formulation comprising amorphous atorvastatin calcium and the process of stabilization of atorvastatin calcium in an amorphous form is described.Type: ApplicationFiled: October 10, 2003Publication date: April 22, 2004Inventors: Rok Grahek, Andrej Bastarda Podlipa, Mateja Salobir
-
Patent number: 6695969Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as and antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergilus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicilium genus, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment.Type: GrantFiled: January 3, 2001Date of Patent: February 24, 2004Assignee: LEK Pharmaceuticals d.d.Inventors: Rok Grahek, Dusan Milivojevic, Andrej Bastarda
-
Patent number: 5854390Abstract: The present invention discloses a new method for the purification of vancomycin hydrochloride by preparative HPLC (method of displacement chromatography), whereby the chromatographic purity of the product is essentialy improved.The chromatography is performed on a reverse stationary phase with a mobile phase consisting of an organic or inorganic acid or of a buffer with possible additives, with different displacing agents, at a defined pH and temperature as well as the amount and concentration of vancomycin hydrochloride.The process is distinguished by the excellent yield and exceptional chromatographic purity 95.5% area of the obtained product and, besides, it represents an ecologically irreproachable process.The vancomycin hydrochloride purified according to the present invention is useful for all types of application since the portion of impurities it contains is for one third lower than in hitherto known commercially available products.Type: GrantFiled: July 28, 1997Date of Patent: December 29, 1998Assignee: LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d.Inventors: Rok Grahek, Andrej Bastarda